Loading people...
David Epstein is a Partner at Flagship Pioneering, a leading life science venture creation firm. He is known for his strategic leadership in building groundbreaking biotech companies and his prior role as CEO of Novartis Pharmaceuticals.
David Epstein, through Flagship Pioneering, focuses on creating and nurturing novel biotech companies. These ventures typically develop transformative therapeutic platforms and address significant unmet medical needs across various disease areas, rather than investing in existing firms.
David Epstein works as a Partner at Flagship Pioneering, a venture creation firm headquartered in Cambridge, Massachusetts, dedicated to originating and building breakthrough life science companies.
David Epstein is a Partner at Flagship Pioneering, a life sciences venture creation firm based in Cambridge, Massachusetts. He previously served as the Chief Executive Officer of Seagen, where he successfully directed the biotechnology company through its $43 billion corporate acquisition by Pfizer in late 2023. Prior to this major transaction, Epstein spent over 25 years at Novartis, ultimately operating as the Chief Executive Officer of the Novartis Pharmaceuticals division from 2010 to 2016. During his extensive executive tenure at the organization, he established its global oncology division and directly oversaw the clinical development and commercial launch of more than 30 new molecular entities. He holds a Master of Business Administration degree from Columbia Business School, and his current professional work focuses on biopharma venture creation, global drug commercialization, and strategic leadership within the broader oncology sector.
David Epstein stands as a distinguished Partner at Flagship Pioneering, a firm renowned for its unique approach to life science innovation: the systematic creation of groundbreaking biotech companies from scratch. In his pivotal role, Mr. Epstein is instrumental in Flagship's distinctive venture creation model, which involves identifying scientific white spaces, incubating novel concepts, and building companies from the ground up. He provides strategic leadership and deep industry knowledge, guiding the development of Flagship's portfolio companies from their earliest stages through significant growth milestones. His expertise ensures these ventures are not only scientifically sound but also strategically positioned to deliver significant impact in human health.
Before joining Flagship Pioneering in 2017, David Epstein forged a highly distinguished career in the global pharmaceutical industry. Most notably, he served as CEO of Novartis Pharmaceuticals, a multi-billion dollar global leader in healthcare. During his extensive tenure at Novartis, he oversaw a vast portfolio spanning numerous therapeutic areas, including oncology, immunology, and neuroscience. He played a key role in numerous product launches, strategic acquisitions, and global market expansions, gaining unparalleled experience in drug development, commercialization, and global market access. This profound background provides an invaluable perspective to Flagship's pioneering efforts, allowing him to identify critical opportunities and navigate complex industry landscapes.
At Flagship, Epstein's focus is on fostering the creation of companies that challenge conventional approaches to medicine and biology. This includes ventures developing novel therapeutic platforms, exploring new modalities like gene editing or synthetic biology, and targeting diseases with high unmet needs, such as oncology, rare genetic disorders, and neurodegenerative conditions. He is deeply involved in the strategic direction of these nascent companies, helping to shape their scientific agendas, build robust business models, and attract top-tier talent. Rather than traditional "investments" in existing companies, his work involves co-founding and nurturing these ventures, guiding them from scientific concept to clinical reality. His leadership is crucial in Flagship's mission to originate and develop companies that redefine biotechnology, ultimately aiming to deliver transformative medicines and solutions to patients worldwide. Through his strategic vision and operational acumen, David Epstein continues to drive innovation at the forefront of the life sciences.
